Form 4 for DMII Drugs Made In America Acquisition II Corp.
Accepted 2025-10-01 00:00:00 ET · period of report 2025-09-26 · accession 0001213900-25-094430 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-01 | 2025-09-26 | DMII | Drugs Made In America Acquisition II LLC | 10% | P - Purchase | — | +700.0K | 15.07M | +5% | — |
| D | 2025-10-01 | 2025-09-26 | DMII | Drugs Made In America Acquisition II LLC | 10% | J - Other | — | -400.0K | 14.68M | -3% | — |
| D | 2025-10-01 | 2025-09-26 | DMII | Drugs Made In America Acquisition II LLC | 10% | S - Sale | — | -7.97M | 6.71M | -54% | — |
| D | 2025-10-01 | 2025-09-26 | DMII | Drugs Made In America Acquisition II LLC | 10% | P - Purchase | — | +700.0K | 700.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary shares | 2025-09-26 | P | A | 700,000 | — | 15,075,000 | D | — | — | (F1) Reflects 700,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000. |
| 2 | Common | Ordinary shares | 2025-09-26 | J | D | 400,000 | — | 14,675,000 | D | — | — | (F2) As of the Transaction Date, the reporting person transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration. |
| 3 | Common | Ordinary shares | 2025-09-26 | S | D | 7,966,667 | — | 6,708,333 | D | — | — | (F3) As of the Transaction Date, pursuant to share transfer agreements, the reporting person transferred an aggregate of 7,966,667 ordinary shares to a number of accredited investors for consideration ranging from no consideration to $1.50 per share. |
| 4 | Derivative | Rights to receive ordinary shares | 2025-09-26 | P | A | 700,000 | — | 700,000 | D | — · — to — | 700,000 Ordinary shares | (F4) The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination. (F1) Reflects 700,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000. |